NCT07021066View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

May 31, 2027

Conditions

Gastric AdenocarcinomaAdvanced Pancreatic Ductal AdenocarcinomaEsophageal AdenocarcinomaBiliary Tract CancerOther Solid Tumors

Interventions

DRUG

BL-M05D1

BL-M05D1 will be administered on D1 every 3 weeks.

Trial Locations (1)

37203

RECRUITING

Sarah Cannon Research Institute - Oncology Partners, Nashville

All Listed Sponsors

lead

SystImmune Inc.

INDUSTRY

NCT07021066 - Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter